| __timestamp | CymaBay Therapeutics, Inc. | Novavax, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 8185000 | 19928000 |
| Thursday, January 1, 2015 | 8871000 | 30842000 |
| Friday, January 1, 2016 | 9645000 | 46527000 |
| Sunday, January 1, 2017 | 12387000 | 34451000 |
| Monday, January 1, 2018 | 14381000 | 34409000 |
| Tuesday, January 1, 2019 | 19238000 | 34417000 |
| Wednesday, January 1, 2020 | 17425000 | 145290000 |
| Friday, January 1, 2021 | 23040000 | 298358000 |
| Saturday, January 1, 2022 | 25116000 | 488691000 |
| Sunday, January 1, 2023 | 51953000 | 468946000 |
In pursuit of knowledge
In the ever-evolving biotech industry, understanding financial trends is crucial. This analysis compares the Selling, General, and Administrative (SG&A) expenses of CymaBay Therapeutics, Inc. and Novavax, Inc. from 2014 to 2023. Over this period, Novavax's SG&A expenses surged by over 2,250%, peaking in 2022 with a staggering 488 million dollars. In contrast, CymaBay's expenses grew by approximately 535%, reaching 52 million dollars in 2023. This stark difference highlights Novavax's aggressive expansion and operational scaling, especially during the COVID-19 pandemic, which necessitated increased administrative costs. Meanwhile, CymaBay's steady growth reflects a more conservative approach, focusing on sustainable development. These insights underscore the diverse strategies within the biotech sector, offering valuable lessons for investors and industry stakeholders.
Eli Lilly and Company and Novavax, Inc.: SG&A Spending Patterns Compared
Selling, General, and Administrative Costs: Novo Nordisk A/S vs CymaBay Therapeutics, Inc.
Selling, General, and Administrative Costs: Alnylam Pharmaceuticals, Inc. vs CymaBay Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Incyte Corporation and Novavax, Inc.
Comparing SG&A Expenses: BioMarin Pharmaceutical Inc. vs Novavax, Inc. Trends and Insights
Cost Management Insights: SG&A Expenses for Catalent, Inc. and CymaBay Therapeutics, Inc.
Catalent, Inc. or Novavax, Inc.: Who Manages SG&A Costs Better?
Comparing SG&A Expenses: CymaBay Therapeutics, Inc. vs PTC Therapeutics, Inc. Trends and Insights
Breaking Down SG&A Expenses: CymaBay Therapeutics, Inc. vs Wave Life Sciences Ltd.
SG&A Efficiency Analysis: Comparing CymaBay Therapeutics, Inc. and Taro Pharmaceutical Industries Ltd.
Rhythm Pharmaceuticals, Inc. or Novavax, Inc.: Who Manages SG&A Costs Better?
Xencor, Inc. and Novavax, Inc.: SG&A Spending Patterns Compared